RPA1 and cancer: Conversely, Conversely, in BRCA-mutant cancers, DNMT1 promotes resistance to PARP inhibitors (PARPi) by modulating DNA repair processes such as RPA complex recruitment and replication fork stability; thus, DNMT1 inhibition sensitizes tumors to PARPi [78].